Indaptus Therapeutics (INDP) Net Income (2020 - 2026)
Indaptus Therapeutics (INDP) posted quarterly Net Income of -$2.2 million for Q1 2026, up 51.77% year-over-year from -$1.5 million in Q1 2025, and up 72.89% quarter-over-quarter from -$8.2 million in Q4 2025.
Indaptus Therapeutics (INDP) Net Income (2020 - 2026) Analysis & Trends
Indaptus Therapeutics' Net Income history runs 7 years deep, the most recent figure standing at -$2.2 million for Q1 2026.
- In Q1 2026, Net Income rose 51.77% year-over-year to -$2.2 million; the TTM figure through Mar 2026 stood at -$18.3 million (down 11.19% YoY), while the FY2025 annual figure was -$80.6 million, down 11.42% from the prior year.
- Net Income for Q1 2026 stood at -$2.2 million, up from -$8.2 million in the prior quarter.
- The five-year high for Net Income was -$2.2 million in Q1 2026, with the low at -$8.2 million in Q4 2025.
- The 5-year median for Net Income is -$4.2 million (2024), against an average of -$4.2 million.
- The sharpest annual moves came in 2025 and 2026: Net Income plunged 94.88% in 2025, then surged 51.77% in 2026.
- Indaptus Therapeutics' Net Income stood at -$3.9 million in 2022, then decreased by 7.04% to -$4.2 million in 2023, then increased by 0.18% to -$4.2 million in 2024, then slumped by 94.88% to -$8.2 million in 2025, then soared by 72.89% to -$2.2 million in 2026.
- Business Quant data shows INDP's Net Income at -$2.2 million in Q1 2026, -$8.2 million in Q4 2025, and -$2.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.35 Bn | 131.49 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 86.24 Bn | 78.25 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.83 Bn | 53.69 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.44 Bn | - | 81.49 Mn |
| 10 | Indaptus Therapeutics | 147.49 Mn | 135.93 Mn | - | -1.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.84 Mn |
| Mar 31, 2026 | -2.22 Mn |
| Dec 31, 2025 | -8.18 Mn |
| Sep 30, 2025 | -2.66 Mn |
| Jun 30, 2025 | -5.26 Mn |
| Mar 31, 2025 | -4.60 Mn |
| Dec 31, 2024 | -4.20 Mn |
| Sep 30, 2024 | -3.25 Mn |
| Jun 30, 2024 | -4.42 Mn |
| Mar 31, 2024 | -4.36 Mn |
| Dec 31, 2023 | -4.20 Mn |
| Sep 30, 2023 | -4.80 Mn |
| Jun 30, 2023 | -3.62 Mn |
| Mar 31, 2023 | -4.27 Mn |
| Dec 31, 2022 | -3.93 Mn |
| Sep 30, 2022 | -3.51 Mn |
| Jun 30, 2022 | -4.02 Mn |
| Mar 31, 2022 | -3.51 Mn |
| Dec 31, 2021 | -3.24 Mn |
| Sep 30, 2021 | -4.39 Mn |